Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination.

Kobayashi, Seiji; Fugo, Kazunori; Yamazaki, Kazuto; Terawaki, Hiroyuki

Kobayashi, Seiji; Fugo, Kazunori; Yamazaki, Kazuto; Terawaki, Hiroyuki.

Afiliación

Kobayashi S; Division of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.
Fugo K; Department of Pathology, Teikyo University Chiba Medical Center, Chiba, Japan.
Yamazaki K; Department of Pathology, Teikyo University Chiba Medical Center, Chiba, Japan.
Terawaki H; Division of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.

Clin Kidney J ; 14(12): 2606-2607, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34938534

Palabras clave

COVID-19; mRNA-based Pfizer-BioNTech COVID-19 vaccine; minimal change disease; nephrotic syndrome; pharmacovigilance; steroid therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Clin Kidney J Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Clin Kidney J Año: 2021 Tipo del documento: Article País de afiliación: Japón